Tag Archives: Vascular Biogenics

H.C. Wainwright Keeps a Buy Rating on Vascular Biogenics (VBLT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report) today and set a price target of $3. The company’s shares opened today at $1.10, equals to its 52-week low of $1.10. Ramakanth observed:

Vascular Biogenics (VBLT) Gets a Hold Rating from H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Vascular Biogenics (NASDAQ: VBLT) today and set a price target of $3. The company’s shares closed on Friday at $1.65, close to its 52-week low of $1.58. According to TipRanks.com,

H.C. Wainwright Downgrades Vascular Biogenics to Hold

H.C. Wainwright analyst Swayampakula Ramakanth downgraded Vascular Biogenics (NASDAQ: VBLT) to Hold today and set a price target of $3. The company’s shares opened today at $2.40, close to its 52-week low of $2.30. According to TipRanks.com, Ramakanth is a

H.C. Wainwright Assigns a Buy Rating on Vascular Biogenics

In a report released today, Swayampakula Ramakanth from H.C. Wainwright assigned a Buy rating to Vascular Biogenics (NASDAQ: VBLT), with a price target of $11. The company’s shares closed yesterday at $6.95. According to TipRanks.com, Ramakanth is ranked 0 out

Analysts Offer Insights on Healthcare Companies: Vascular Biogenics (NASDAQ: VBLT), CymaBay Therapeutics (NASDAQ: CBAY) and Recro Pharma (NASDAQ: REPH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vascular Biogenics (NASDAQ: VBLT), CymaBay Therapeutics (NASDAQ: CBAY) and Recro Pharma (NASDAQ: REPH) with bullish sentiments. Vascular Biogenics (NASDAQ: VBLT) In a

Vascular Biogenics Receives a Perform from Oppenheimer

Oppenheimer analyst Wendy Lam reiterated a Perform rating on Vascular Biogenics (NASDAQ: VBLT) yesterday. The company’s shares closed yesterday at $5.44. Lam observed, “VBLT reported 3Q15 loss per share of ($0.29) and ended the quarter with $27.6M in cash, cash